Barclays raised the firm’s price target on Exelixis (EXEL) to $40 from $29 and keeps an Equal Weight rating on the shares. The firm updated the company’s model to reflect a higher probability of sucess in colorectal cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
- RBC downgrades Exelixis on valuation ahead of Cabometyx cliff
- Exelixis downgraded to Sector Perform from Outperform at RBC Capital
- Truist biotech analyst holds an analyst/industry conference call
- Exelixis price target raised to $53 from $47 at H.C. Wainwright